The UK body that decides which drugs are cost-effective is often attacked when it decides new treatments that offer only small benefits aren’t worth a high price. But in an interview published in the Observer this weekend, Sir Michael Rawlins, the chairman of the National Institute for Health and Clinical Excellence (NICE), comes out swinging.
“We [...]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment